Fermenta Biotech (FERMENTA) had a P/E of 21.5× on 6 Nov 2026, below the industry P/E of 28.7×, and the shares are 23% below their 52-week high. Its ROCE of 24% is the highest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales grew 14% a year over 3 years. Its dividend yield is 0.9%, and debt is 0.28× equity. It is a small-cap company with a market cap of ₹1,282 Cr, ranked 67th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 1.7% over the past year.
- ₹410.10
- ₹455.00
- ₹401.40
- ₹416.40
- 3.6 L
Health check
- ReturnsBehind
−1.7% over a year, better than 1 of 7 peers.
- Price tagCheaper
P/E 21.5 vs industry 28.7.
- GrowthStrong
Sales +14.5% a year over 3 years.
- ProfitabilityStrong
ROCE 24.2% vs peer median 17.9%.
- Balance sheetSolid
Debt 0.28× equity, interest covered 10.3×, Piotroski 7 of 9.
- Red flags3 to check
Quarterly profit down 55.4% on a year ago.
Small cap
Market sensitivity
Key metrics
- Market cap
- ₹1,282 Cr
- Small cap
- P/E
- 21.5
- Industry 28.7
- Price to book
- 3.15
- Peers 4.99
- Dividend yield
- 0.90%
- ROE
- 18.7%
- Peers 14.7%
- ROCE
- 24.2%
- Peers 17.9%
- Debt to equity
- 0.28
- Debt ₹113 Cr
- EPS (TTM)
- ₹20.72
- Face value ₹5
- OPM (TTM)
- 17.5%
- Net margin 11.7%
- Sales growth
- −10.6%
- Latest quarter vs a year ago
- Profit growth
- −55.4%
- Latest quarter vs a year ago
- Price to sales
- 2.51
- EV/EBITDA 15.3
Strengths and risks
Strengths
- Return on equity of 18.7%.
- Return on capital employed of 24.2%.
- Positive operating cash flow in each of the last 4 years.
Risks to check
- Quarterly profit down 55.4% on a year ago.
- Quarterly sales down 10.6% on a year ago.
- Promoter stake down from 64.1% to 60.1%.
About Fermenta Biotech
Fermenta Biotech Limited, together with its subsidiaries, engages in the manufacturing and marketing of chemicals, bulk drugs, enzymes, pharmaceutical formulations, and environmental solution products in India, Europe, the United States, and internationally. It operates through Chemicals/Bulk Drug and Property segments. The company offers vitamin D3, including crystalline oil, resin oil, cold water dispersible, and feed grade powder for injectables, soft…
- Headquarters
- Thane
- Employees
- 630
- Sector
- Healthcare
- ISIN
- INE225B01021
- Website
- fermentabiotech.com
Price range
- Avg volume (3M)
- 2.3 L
- 1-year return
- minus 1.7%
- From 52-week high
- minus 23.4%
Peers · Drug Manufacturers - Specialty & Generic
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | 1,860.00 | plus 1.69% | 4,46,276 | 40.7 | 4.99 | 17.9% | 13.1% | 28.2% | 10.4% | 10.6% | 0.86% | plus 8.2% |
| DIVISLABDivi's Laboratories | 10,320.50 | plus 1.78% | 2,73,977 | 93.6 | 16.35 | 19.0% | 16.2% | 34.9% | 11.0% | 12.1% | 0.29% | plus 49.0% |
| TORNTPHARMTorrent Pharmaceuticals | 4,750.00 | plus 0.85% | 1,80,675 | 80.2 | 9.83 | 9.1% | 15.7% | 33.7% | 13.3% | 20.2% | 0.80% | plus 31.7% |
| LAURUSLABSLaurus Labs | 2,340.00 | minus 0.26% | 1,26,433 | 94.4 | 20.86 | 19.5% | 24.0% | 30.4% | 3.8% | 4.0% | 0.09% | plus 138.6% |
| ZYDUSLIFEZydus Lifesciences | 1,197.90 | plus 0.41% | 1,19,491 | 28.6 | 4.29 | 19.0% | 14.7% | 26.2% | 16.5% | 37.0% | 0.08% | plus 22.8% |
| DRREDDYDr. Reddy's Laboratories | 1,373.00 | plus 0.51% | 1,14,462 | 40.9 | 2.96 | 14.2% | 7.3% | 15.9% | 11.0% | −1.7% | 0.58% | plus 13.8% |
| CIPLACipla | 1,411.00 | plus 0.49% | 1,13,993 | 39.4 | 3.22 | 14.9% | 8.3% | 17.3% | 7.2% | 11.5% | 0.92% | minus 6.6% |
| FERMENTAFermenta Biotech | 446.40 | plus 7.20% | 1,282 | 21.5 | 3.15 | 24.2% | 18.7% | 17.5% | 14.5% | – | 0.90% | minus 1.7% |
| Median of 7 peers | – | 0.51% | 1,26,433 | 40.9 | 4.99 | 17.9% | 14.7% | 28.2% | 11.0% | 11.5% | 0.58% | 22.8% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 136 | 130 | 137 | 122 | 122 | |
| 108 | 104 | 112 | 102 | 104 | |
| 28.2 | 26.6 | 25 | 20 | 18.1 | |
| 20.7% | 20.5% | 18.2% | 16.5% | 14.8% | |
| 8.8 | 5.4 | 3.1 | 5.1 | 4.4 | |
| 3.1 | 2.6 | 3 | 2.8 | 2.5 | |
| 5.8 | 5.4 | 5.4 | 5.1 | 5.2 | |
| – | – | −2.2 | 9.1 | – | |
| 28.1 | 24.1 | 17.5 | 26.2 | 14.7 | |
| 23.1% | 25.1% | 31.2% | 29.0% | 35.1% | |
| 21.8 | 18.9 | 12.7 | 19.2 | 9.7 | |
| 7.47 | 6.43 | 4.34 | 6.61 | 3.34 |
Profit & loss
- Sales CAGR 3Y
- +14.5%
- ROE
- 18.7%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 349 | 333 | 467 | 524 | |
| – | minus 4.5% | +40.1% | +12.1% | |
| 322 | 299 | 350 | 419 | |
| 27.2 | 34.1 | 118 | 105 | |
| 7.8% | 10.2% | 25.2% | 20.0% | |
| 2.7 | 4.4 | 6.6 | 13.7 | |
| 19 | 15.9 | 13.2 | 10.3 | |
| 28.2 | 24.7 | 24.2 | 21.7 | |
| −34 | −7.7 | −3.5 | 9.6 | |
| −51.3 | −9.9 | 83.2 | 95.9 | |
| −3.6% | −143.2% | 8.2% | 26.7% | |
| −51.1 | −23.1 | 76.9 | 71.8 | |
| -17.70 | -7.99 | 26.35 | 24.51 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 14.4 | 14.4 | 14.6 | 14.3 | |
| 301 | 274 | 348 | 392 | |
| 220 | 139 | 115 | 113 | |
| 102 | 120 | 137 | 128 | |
| 637 | 548 | 614 | 648 | |
| 260 | 254 | 232 | 224 | |
| 43 | 1.8 | 16.1 | 13.5 | |
| 1.8 | 1.1 | 2 | 2 | |
| 60.1 | 59.8 | 70.7 | 83 | |
| 272 | 231 | 293 | 325 | |
| 637 | 548 | 614 | 648 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 116 | 105 | 40.9 | 92.8 | |
| −55.4 | −15.5 | −0.2 | −43 | |
| −41.4 | −90.9 | −50.9 | −42.3 | |
| 19.3 | −1 | −10.1 | 7.5 | |
| −40.5 | −19.2 | −22.1 | −30.3 | |
| 75.6 | 86.1 | 18.8 | 62.5 | |
| −4.2 | −3.6 | −3.6 | −7.3 |
Shareholding pattern
- Promoters60.12%
- Public37.49%
- Employee trusts2.39%
| Quarter | Split | Promoters | Public | Promoter change |
|---|---|---|---|---|
| 30 Sep 2026 | 60.12% | 37.49% | minus 3.97 | |
| 3 Aug 2026 | 64.09% | 33.36% | – |
Major shareholders
Filings & events
News
No recent news coverage found.